Avidity Biosciences, Inc. (RNA)
| Market Cap | 1.56B |
| Revenue (ttm) | 8.31M |
| Net Income (ttm) | -162.06M |
| Shares Out | 66.46M |
| EPS (ttm) | -3.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 810,882 |
| Open | 22.34 |
| Previous Close | 22.46 |
| Day's Range | 22.12 - 23.97 |
| 52-Week Range | 9.83 - 23.94 |
| Beta | -0.04 |
| Analysts | Buy |
| Price Target | 44.15 (+88.11%) |
| Earnings Date | Mar 7, 2023 |
About RNA
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme t... [Read more]
Financial Performance
In 2021, RNA's revenue was $9.33 million, an increase of 37.41% compared to the previous year's $6.79 million. Losses were -$118.01 million, 166.1% more than in 2020.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for RNA stock is "Buy." The 12-month stock price forecast is $44.15, which is an increase of 88.11% from the latest price.
News
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Jan. 20, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C...
Avidity Biosciences, Inc. Announces Pricing of Upsized Public Offering of Common Stock
SAN DIEGO , Dec. 15, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C...
Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock
SAN DIEGO , Dec. 15, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C...
Avidity's stock rallies 39% on new RNA data
Shares of Avidity Biosciences Inc. RNA, -4.52% soared 39% in premarket trading on Wednesday after the company said its experimental RNA therapy, when injected into the muscle, has potential as a treat...
If we do enter a recession next year, we'll see more of a rotation into health care, says RTW's Wong
Dr. Rod Wong, RTW Investments managing partner and CIO, joins the 'Halftime Report' to discuss his thoughts on the biotech sector going into the new year, his investing thesis behind Avidity Bioscienc...
Down 15.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Avidity Biosciences, Inc. (RNA)
The heavy selling pressure might have exhausted for Avidity Biosciences, Inc. (RNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall S...
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Tops Revenue Estimates
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 15.46% and 3.85%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the s...
Avidity Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights
Company has three distinct rare disease programs in clinical development - myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD) On trac...
Avidity Biosciences to Participate in Upcoming Investor Conferences
SAN DIEGO , Nov. 1, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Co...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avidity Biosciences, Inc. - RNA
NEW YORK , Oct. 19, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Avidity Biosciences, Inc. ("Avidity" or the "Company") (NASDAQ: RNA). Such investors are advis...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avidity Biosciences, Inc. - RNA
New York, New York--(Newsfile Corp. - October 8, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Avidity Biosciences, Inc. ("Avidity" or the "Company") (NASDAQ: RNA). Such inve...
Avidity Biosciences Announces Upcoming Presentations at 27th International Hybrid Annual Congress of World Muscle Society
SAN DIEGO , Oct. 6, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Co...
SHAREHOLDER ALERT: Investigation of Avidity (RNA) Announced by Holzer & Holzer, LLC
Atlanta, Georgia--(Newsfile Corp. - September 29, 2022) - Holzer & Holzer, LLC is investigating whether Avidity Biosciences, Inc. ("Avidity" or the "Company") (NASDAQ: RNA) complied with federal secur...
Avidity (RNA) Down on Partial Hold of Myotonic Dystrophy Study
Avidity Biosciences (RNA) reports FDA-imposed partial hold on enrolling new patients in its phase I/II MARINA study evaluating AOC 1001 in myotonic dystrophy type 1 in adults. Stock down.
Avidity shares fall 23% after announcing partial clinical hold for myotonic dystrophy trial
Shares of Avidity Biosciences Inc. RNA, +1.13% tumbled 23.7% in premarket trading on Tuesday after the company said the Food and Drug Administration placed a partial clinical hold on new enrollment in...
Avidity Biosciences Announces FDA Partial Clinical Hold on New Participant Enrollment in Phase 1/2 MARINA™ Trial
Participants currently enrolled in MARINA and MARINA-OLE™ trials may continue to be treated with AOC 1001 Avidity received Investigational New Drug (IND) clearance for FSHD and DMD studies from FDA; p...
7 Unknown Biotech Stocks That Could Rocket in 2023
Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.
Avidity Biosciences Engages with Patient Communities During National Muscular Dystrophy Awareness Month as part of Commitment to Developing Muscular Dystrophy Programs
Company remains on track to have three muscular dystrophy programs in clinic by end of year SAN DIEGO, Sept. 7, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical compa...
Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Lags Revenue Estimates
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -24.32% and 4.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock...
Avidity Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
Company remains on track to have three programs in the clinic by the end of this year Programs are for three distinct rare diseases - myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dyst...
Avidity Biosciences Enrolls Patients in the MARINA™ Open-Label Extension Study
Adults with myotonic dystrophy type 1 (DM1) in the AOC 1001 Phase 1/2 MARINA™ clinical trial can receive continuity of care as part of MARINA-OLE™ Preliminary assessment of safety, tolerability and ke...
Avidity Biosciences, Inc. (RNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Avidity Biosciences, Inc. (RNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes Avidity Biosciences, Inc. (RNA) a New Buy Stock
Avidity Biosciences, Inc. (RNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Chardan Initiates Coverage On These 'Intriguing Small-Cap Stories"
Chardan Research initiated coverage on Avidity Biosciences Inc (NASDAQ: RNA) with a Buy rating and a price target of $29 and Dyne Therapeutics Inc (NASDAQ: DYN) with a Buy rating and a price target of...
Avidity Biosciences Supports World Facioscapulohumeral Muscular Dystrophy (FSHD) Day and Presents Preclinical Data from FSHD Program
Oral Presentation at FSHD IRC highlights preclinical data that demonstrated prevention of muscle weakness by reducing DUX4 expression AOC 1020 on track to be in the clinic by end of 2022 for the treat...